Scalper1 News
Specialty drugmaker Salix Pharmaceuticals announced on Oct. 3 that it was doing something unusual: backing out of a merger before it closed. Back in July, Salix (SLXP) had agreed to acquire Cosmo Technologies, the Irish subsidiary of Italian drugmaker Cosmo Pharmaceuticals, in a stock swap valued at about $2.6 billion. The deal would have allowed Salix, like so many of its drug-industry peers, to move its official domicile to Scalper1 News
Scalper1 News